Eight Roads India

Eight Roads is a global venture firm with a dedicated $250 million India healthcare and life sciences fund launched in May 2022, focused exclusively on innovative life sciences and digital health startups. The firm’s documented investments include HiLabs (the AI-powered healthcare data management company that closed a $39M Series B co-led by Eight Roads in March 2024), Bicara Therapeutics, Caplin Steriles, Carestack, Cipla Health, Doceree, Elucidata, Immuneel Therapeutics, OZiva, PharmEasy, and other category leaders across the Indian healthcare and life sciences value chain. Check sizes of $5M to $25M and a stage focus on Series A through growth reflect the firm’s institutional Series A and growth-stage posture.

The firm’s natural fit is with Indian healthcare and life sciences founders running Series A-ready or later companies with credible commercial or scientific traction. For digital health founders, the right profile is a team with strong revenue, retention, and unit economics in a defined healthcare software or care delivery category. For life sciences founders, the right profile is a team with credible scientific platform, IP, and a clear commercial or therapeutic development path. Founders below Series A scale, US-only founders without Indian commercial relevance, and founders building outside the healthcare and life sciences value chain are not the natural target.

Geographically, Eight Roads has the broadest healthcare portfolio in India among non-domestic specialist funds, with a multi-decade track record of backing Indian healthcare leaders. The firm’s connectivity to global Eight Roads infrastructure (Fidelity-affiliated, multi-region) provides credible follow-on syndication and exit optionality. For Indian-anchored healthcare founders, the firm is among the most thoughtful institutional partners on the continent.

The right entry path is via an investment banker leading the round, an existing portfolio founder, or a senior operator at one of the Indian healthcare unicorns. The firm reads partner-led decks at institutional pace. The pitch should lead with revenue, gross margin, retention metrics, scientific or commercial differentiation, and a credible follow-on plan. AI narrative should connect to specific clinical or operational outcomes.

Caveats. The firm’s institutional posture means partner attention is concentrated on category leaders; founders without Series A scale should approach later. Healthcare-specific governance preferences in regulated assets are well-developed at Eight Roads; engage experienced counsel. The dedicated $250M India healthcare fund mandate means the firm will deploy with discipline; confirm current vintage status and dry powder via direct conversation. For Indian healthcare and life sciences category leaders at Series A and beyond, Eight Roads India is among the strongest specialist partners available; for early-stage or non-Indian founders, the fit is weaker.